Tag: REN001

Reneo Pharmaceuticals Raises $95 Million in Series B Financing, Co-led by Novo Ventures and Abingworth

Gregory J. Flesher Appointed President and Chief Executive Officer   SAN DIEGO, December 9, 2020 – Reneo Pharmaceuticals, Inc. today announced it raised $95 million in a Series B financing co-led by Novo Ventures and Abingworth and supported by existing investors New Enterprise Associates, RiverVest Venture Partners, Pappas Capital, and Lundbeckfonden Ventures, as well as… Continue reading Reneo Pharmaceuticals Raises $95 Million in Series B Financing, Co-led by Novo Ventures and Abingworth

Reneo Receives Orphan Drug Designations from the EMA for REN001 for the Treatment of LCHAD Deficiency and MELAS Syndrome and Moves Forward with Clinical Trials

A global clinical trial is slated to begin for early next year to evaluate REN001 for the treatment of primary mitochondrial myopathies (PMM), including MELAS syndrome   For LCHAD deficiency and other fatty acid oxidation disorders (FAOD), a Phase 1b clinical trial is currently recruiting and expanding globally and an international observational study is planned… Continue reading Reneo Receives Orphan Drug Designations from the EMA for REN001 for the Treatment of LCHAD Deficiency and MELAS Syndrome and Moves Forward with Clinical Trials

Reneo Pharmaceuticals Completes Clinical Study in Primary Mitochondrial Myopathies and Receives FDA Orphan Drug Designation for REN001

Recently completed clinical study is informing the design of a large, global PMM clinical trial, which is planned to begin early 2021; summary to be presented at UMDF Power Surge 2020   SAN DIEGO, June 23, 2020 – Reneo Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development… Continue reading Reneo Pharmaceuticals Completes Clinical Study in Primary Mitochondrial Myopathies and Receives FDA Orphan Drug Designation for REN001